Table 3.
Primary and secondary endpoints of the entire MedaMACS Study population at 1 year.
| MedaMACS Study (N=161) | |
|---|---|
| Primary Endpoints | |
| Mortality | 27 (17%) |
| Left Ventricular Assist Device (LVAD) received | 13 (8%) |
| Transplant received | 15 (9%) |
| Alive without LVAD or Transplant* | 88 (55%) |
| Unknown* | 18 (11%) |
| Secondary Endpoints | |
| Inotropes required | 22 (14%) |
| At least one rehospitalization | 92 (57%) |
| Total Number of Rehospitalizations | 1.7 ± 2.2 |
*
8 patients withdrew consent; 10 patients transferred to centers not participating in MedaMACS